MetaCap

Atara Biotherapeutics (ATRA) vs Champions Oncology (CSBR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Champions Oncology (CSBR) has outperformed Atara Biotherapeutics (ATRA) over the past year, losing 35.9% versus a loss of 53.7%. Over five years, CSBR leads with a -53.0% price change compared with -98.6% for ATRA. Atara Biotherapeutics is the larger company by market cap ($64.5 million vs $60.4 million), about 1.1 times the size, while Champions Oncology is growing revenue faster (+4.4% vs -6.3%).

On valuation, Atara Biotherapeutics trades at a lower forward P/E (4.0x vs 43.4x for Champions Oncology). Atara Biotherapeutics converts more of its revenue into profit, with a net margin of 27.1% versus -2.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATRA-53.73%CSBR-35.89%
+37%-19%-75%
Nov 21, 20251 yearNov 20, 2026
ATRA-98.62%CSBR-53.68%
+30%-38%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATRA versus CSBR key metrics
MetricATRACSBR
Share price$6.33$4.34
Market cap$64.49M$60.41M
1-day change-0.16%-1.36%
YTD return-65.01%-37.19%
1-year return-53.73%-35.89%
5-year return-98.56%-52.98%
Forward P/E3.9643.40
EPS (TTM)$-1.12$-0.07
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$120.77M$59.42M
Revenue growth (YoY)-6.33%+4.36%
Net income (latest FY)$32.69M$-1.18M
Gross margin—48.00%
Operating margin29.69%-1.92%
Net margin27.07%-1.98%
52-week high$19.15$8.31
52-week low$3.92$4.34
Distance from 52-week high-66.94%-47.77%
Analyst consensusbuy—
Avg. price target upside+115.96%—
Average volume35.46K9.71K
Shares outstanding10.19M13.92M
Employees10214
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CSBR has outperformed ATRA by 17.8 percentage points over the past year.
  • Atara Biotherapeutics is more profitable, keeping 27.1 cents of every revenue dollar as net income versus -2.0 cents for Champions Oncology.
  • Champions Oncology grew revenue faster in its latest fiscal year (+4.36% vs -6.33%).

About Atara Biotherapeutics

ATRA stock →

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees

About Champions Oncology

CSBR stock →

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 214 employees

ATRA vs CSBR FAQ

Which is bigger, Atara Biotherapeutics or Champions Oncology?

Atara Biotherapeutics (ATRA) is larger, with a market capitalization of $64.49M compared with $60.41M for Champions Oncology (CSBR).

Which stock has performed better over the past year, ATRA or CSBR?

CSBR returned -35.89% over the past 12 months, compared with -53.73% for ATRA (price return, excluding dividends). Past performance does not predict future results.

Are Atara Biotherapeutics and Champions Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons